Dr. Maximilian Diehn

Dr. Maximilian Diehn, MD, PhD, is a leading radiation oncologist and physician-scientist, internationally recognized for his pioneering work in liquid biopsy technologies and translational cancer genomics. He serves as Professor of Radiation Oncology at Stanford University School of Medicine and is Co-Director of the Stanford Cancer Institute’s Molecular Diagnostics Program. Dr. Diehn earned his medical degree and PhD in Biophysics from Stanford University, completed his residency in Radiation Oncology at Stanford, and is board-certified in Radiation Oncology. He is widely recognized for advancing non-invasive diagnostic methods that are reshaping cancer detection and monitoring.

Dr. Diehn has been at the forefront of developing ultrasensitive circulating tumor DNA (ctDNA) assays that enable early detection of minimal residual disease, monitor treatment response, and predict relapse across a spectrum of solid tumors. His research has led to key innovations in molecular diagnostics, with his laboratory's techniques now forming the basis for clinical-grade liquid biopsy platforms in oncology. Dr. Diehn’s work bridges fundamental insights in tumor genomics with practical clinical applications, driving forward precision oncology strategies that enhance early intervention and personalized treatment. He has authored over 150 peer-reviewed publications and holds numerous patents in the field of cancer diagnostics.

Beyond his research impact, Dr. Diehn is a dedicated mentor and collaborative leader, guiding the next generation of physician-scientists in oncology and molecular diagnostics. He plays a pivotal role in translational research initiatives that integrate advanced genomic technologies into routine clinical practice, shaping the future of precision medicine in cancer care.